In the BioHarmony Drug Report Database

"Preview" Icon

Ulipristal

Ella, Esmya (ulipristal) is a small molecule pharmaceutical. Ulipristal was first approved as Ella on 2010-08-13. It has been approved in Europe to treat leiomyoma. The pharmaceutical is active against progesterone receptor. Ella’s patents are valid until 2030-06-12 (FDA).

 

Trade Name

 

Esmya
 

Common Name

 

ulipristal
 

ChEMBL ID

 

CHEMBL2103846
 

Indication

 

leiomyoma
 

Drug Class

 

Steriodal compounds acting on progesterone receptors (excluding -gest- compounds)

Image (chem structure or protein)

Ulipristal structure rendering